2565 QoLiTime: Quality-of-Life (QoL) analysis of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel in daily clinical practice. (September 2015) - Hofheinz, R.D.; Al-Batran, S.E.; Windemuth-Kieselbach, C.; Hammerer, P.